Every service below is powered by the same advantage: a practicing surgeon and a seasoned dealmaker, working the same engagement. It's what makes our advice sharper in medicine, in M&A, and in exit planning alike.
We assess how a business actually runs — operationally and financially — and build a prioritized plan to improve margin, de-risk operations, and position the company for a strong valuation whenever a transaction becomes the goal.
Our M&A practice is led by Masih Mehrabi, who has spent his career doing exactly this work for institutional players — directing valuation, due diligence, and deal structuring across private equity, strategy consulting, and corporate development. He has led commercial and financial diligence on 30+ M&A and growth transactions, built the DCF and comps models behind go/no-go decisions, and structured cross-border acquisitions delivering 25–30% IRR.
Now that same discipline works for owners and buyers directly. And when the business is a healthcare one, Masih's financial rigor is paired with Dr. Mallah's surgical and operational insight — so the clinical quality, risk, and workflow that drive a medical practice's real value are assessed by someone who has actually stood in the OR. That combination is what lets us position a practice for a premium multiple, and lets buyers trust the diligence beneath the number.
Dr. Mallah provides case review, written opinion, and testimony for attorneys and insurers, drawing on an active surgical practice rather than a purely academic record — and advises medical device and healthtech innovators on the clinical and regulatory realities of bringing a product to market.
Tell us where your business stands — we'll tell you plainly which of these applies, and which don't.
Book a Free 30-Minute Call →